Andere Sprachen IRLAB Therapeutics AB

Aktien

A2PLBE

SE0012675361

IRLAB A

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 12:59:54 30.04.2024			% 5 Tage	% 1. Jan.
11,4 ^SEK	+1,33 %		-8,06 %	+52,00 %

22.03.	IRLAB Therapeutics erhält Protokoll des End-of-Phase 2 Meetings, das die Übereinstimmung mit der FDA bezüglich des Phase III Programms für Mesdopetam bestätigt	CI
19.03.	IRLAB Therapeutics AB (publ) Mesdopetam zeigt antipsychotische Eigenschaften in einem fortgeschrittenen Modell der Psychose der Parkinson-Krankheit	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

IRLAB publishes Annual Report for 2023	29.04.
IRLAB to present at Redeye Investor Forum	16.04.
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	25.03.
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22.03.
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	22.03.
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19.03.
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	19.03.
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	19.03.
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	29.02.
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	28.02.
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	27.02.
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	22.02.
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22.02.
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	07.02.
IRLAB publishes year-end report for the period January-December 2023	07.02.
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07.02.
IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines	06.02.
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	06.02.
IRLAB, Invitation to the Year-end Report 2023 presentation and webcast	01.02.
IRLAB: Invitation to the Year-end Report 2023 presentation and webcast	31.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen IRLAB Therapeutics AB

Aktien

A2PLBE

SE0012675361

IRLAB A

Andere Sprachen

Filter